HA23 (Sodium Hyaluronate Gel)
HA23
Certificate of Medical Device Registration
Download Product Specs
PRODUCT OVERVIEW:
DVS (DIVINYL SULFONE)
cross-linked hyaluronic ACID
Sterile Absorbable Viscoelastic Gel
HA23 is a sterile viscoelastic gel designed for the treatment of knee osteoarthritis, providing cushioning and lubrication that reduce pain and improve mobility. Formulated with innovative DVS cross-linking technology, it offers enhanced stability, softer injection force, and longer-lasting relief compared to conventional options.
Product Name:
Sterile Absorbable Viscoelastic Gel (Sodium Hyaluronate Gel)
Composition:
4:1 w/w mixed hydrogel of sodium hyaluronate gel crosslinked by Divinyl sulfone and sodium hyaluronate fluid.
Contents:
2.0g (as Sodium Hyaluronate 40mg) in a 2mL pre-filled syringe (with needle 23G).
Indication:
Treatment of Osteoarthritis of the Knee.
Pharmacodynamics
HA23 acts as a lubricant and shock absorber in the joint, reducing pain and improving mobility in patients with osteoarthritis.
Mechanism of Action
The sodium hyaluronate gel mimics the natural synovial fluid, providing cushioning and lubrication to the knee joint, thereby alleviating pain and enhancing joint function.
Dosage and Administration
Administered as a single intra-articular injection into the knee joint.
Features of HA23:
- Soft injection force.
- Continuous lubrication provided by the mixed cross-linked HA gel and natural HA fluid.
Unique Property:
Hydrogel developed through cross-linking technology using Divinyl Sulfone (DVS).
DVS VS. BDDE
DVS (divinyl sulfone) HA23, which features cross-linked hyaluronic acid (HA) gel particles with a size of approximately 300 micrometers.
In contrast, BDDE (1,4-Butanediol diglycidyl ether) results in cross-linked HA gel particles that are about 800 micrometers in size. Both products are designed for use in prefilled syringes for the treatment of osteoarthritis of the knee.
To summarize:
It is important to note that larger particle sizes may lead to increased discomfort during treatment. Therefore, the smaller particle size of DVS (HA23) compared to other competitor BDDE suggests that it may be a less painful option for patients.
This characteristic could make DVS a more attractive choice among competitors for those seeking treatment for osteoarthritis symptoms.
DVS (HA23) ADVANTAGES:
- 1Enhanced stability and longevity of the gel.
- Improved biocompatibility and reduced risk of adverse reactions.
- Superior lubrication properties for joint function.
- Better resistance to degradation over time.
TARGET SPECIALTY
Orthopedics and Rheumatology specialists who treat osteoarthritis in patients.
Your Possible Clients;
- Orthopedic clinics.
- Rheumatology practices.
- Pain management specialists.
- Sports medicine facilities.
WHY HA23?
- Innovative Cross-Linking: Utilizes DVS technology for a more effective and stable product.
- Enhanced Patient Comfort: Soft injection force reduces discomfort during administration.
- Longer Lasting Relief: Continuous lubrication and stability provide prolonged relief from osteoarthritis symptoms.
- Targeted Treatment: Specifically designed for intra-articular use, ensuring optimal delivery to the knee joint.
